Form 4: Jasper Therapeutics COO Granted 90,000 Stock Options

Jasper Therapeutics' Chief Operating Officer, Jeetinder Singh Mahal, was granted 90,000 stock options with an exercise price of $1.84.

Summary

• Jeetinder Singh Mahal, Chief Operating Officer of Jasper Therapeutics, Inc. (JSPR), was granted 90,000 stock options.
• The transaction date for this grant was January 2, 2026.
• The exercise price for these stock options is $1.84 per share.
• The options have an expiration date of January 2, 2036.
• Vesting schedule dictates that 1/4th of the shares subject to the option will vest on January 2, 2027.
• Following the initial vesting, 1/48th of the original number of shares will vest after each subsequent one-month period.
• Vesting is contingent upon the Reporting Person's continuous service to the Issuer through each applicable vesting date.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive event as it aligns management's interests with shareholders and provides a long-term incentive for performance. It is a standard compensation practice and does not indicate any immediate negative operational or financial issues.

Positives

• The grant of stock options to the Chief Operating Officer aligns management's long-term interests with those of the shareholders.
• Provides a performance incentive for the executive to contribute to the company's growth and stock price appreciation.

Risks

• The value of the stock options is dependent on the future market price of Jasper Therapeutics' common stock, which may fluctuate.
• Options may be forfeited if the Reporting Person's continuous service to the Issuer ceases before all options are vested.

Future Outlook

The stock option grant provides a long-term incentive for the Chief Operating Officer, aligning their financial interests with the future performance and growth of Jasper Therapeutics. The vesting schedule encourages continued service and contribution to the company's strategic objectives.

Industry Context

The grant of stock options to key executives is a common practice in the biotechnology and pharmaceutical industries, particularly for companies like Jasper Therapeutics that are often in development stages. This compensation structure is designed to attract, retain, and motivate talent by linking executive rewards to shareholder value creation.

Comparison to Industry Standards

• Executive equity compensation, such as stock option grants, is a standard practice across the biotech and pharmaceutical sectors, comparable to similar grants observed at companies like Moderna, BioNTech, or smaller clinical-stage biotechs.
• The vesting schedule, with an initial cliff and subsequent monthly vesting, is a typical structure used to ensure long-term commitment from executives, similar to plans at companies such as Gilead Sciences or Amgen for their senior leadership.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Operating Officer's financial incentives with shareholder value creation, potentially leading to more focused efforts on company growth.
• Employees: May signal stability in executive leadership and a commitment to long-term strategic goals.

Next Steps

• The Chief Operating Officer will continue to serve the company, with options vesting according to the specified schedule.
• Potential future exercise of vested options by the Reporting Person.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to an existing executive as part of their compensation package. While it aligns management incentives with shareholder interests, it does not present new material information that would fundamentally alter the investment thesis for Jasper Therapeutics. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals and market conditions rather than this specific compensation event.

Keywords

Jasper Therapeutics, JSPR, Stock Options, Executive Compensation, Insider Trading, Form 4, Equity Grant, Jeetinder Mahal